Strict regulatory controls designed to curb pharmaceutical misuse and diversion are inadvertently creating severe logistical barriers for patients living with chronic neurological conditions, frequently triggering preventable treatment interruptions and dangerous breakthrough seizures. In a qualitative descriptive investigation embedded within the MINDSET 2.0 randomized controlled trial, published in Frontiers in Public Health, researchers led by Dr. Refugio Sepulveda examined how federal and state controlled-substance frameworks intersect with the everyday realities of chronic disease management. Evaluating in-depth exit interviews from fifty-three adult epilepsy patients across Arizona and Texas, alongside corroborating national clinician data, the investigative team discovered that rigid dispensing rules routinely collide with insurance limitations and pharmacy inventory shortages.
The underlying statutory tension stems from the Controlled Substances Act, which categorizes pharmaceuticals into five distinct schedules according to their recognized medical utility, relative abuse liability, and physical or psychological dependence potential. When a therapeutic agent is scheduled under federal law, the classification automatically triggers intensive regulatory mandates, including rigorous provider recordkeeping, strict limits on refill timing, and prohibitions against early dispensing. Although these diversion safeguards fulfill an essential population-level public health function by limiting illicit distribution, the authors emphasize that uniform statutory restrictions fail to account for the acute clinical sensitivity of chronic conditions such as epilepsy. The central policy dilemma identified by the research team is not whether controlled-substance diversion safeguards are fundamentally necessary, but whether the friction imposed by existing operational mechanics is proportionate to the real-world misuse risk of modern antiepileptic therapies.
To capture the authentic, low-inference lived experiences of individuals subject to these regulatory controls, the study investigators utilized a qualitative descriptive research design nested within the broader MINDSET 2.0 intervention trial. The parent randomized controlled trial originally enrolled one hundred nineteen adults diagnosed with epilepsy through neurology clinics affiliated with Banner University Medical Center in Arizona and the Epilepsy Foundation Central and South Texas. Among sixty-three participants allocated to the web-based self-management intervention arm, fifty-three completed the trial protocol and participated in comprehensive semi-structured exit interviews exploring their experiences implementing clinical self-management recommendations. Transcripts were analyzed through thematic content analysis using NVivo 12 software, employing independent dual coding, collaborative team reconciliations, and constant comparative techniques until full thematic saturation was achieved. Spanish-language interviews were independently translated into English by two bilingual researchers and consolidated through consensus review, ensuring that participants’ personal accounts of navigating pharmacy systems, prescriber communications, and regulatory barriers were documented with meticulous methodological rigor.
The demographic profile of the fifty-three interview participants illustrates how regulatory friction intersects with distinct socioeconomic and structural vulnerabilities across diverse patient cohorts. The cohort had a mean age of 48.96 years with an overall range spanning twenty-one to seventy-nine years, with women comprising 62.26 percent and men representing 37.74 percent of the sample. In terms of racial and ethnic composition, 73.58 percent identified as non-Hispanic or non-Latino, 26.42 percent identified as Hispanic or Latino, and 81.13 percent identified as White. Although educational attainment within the cohort was relatively high, with 77.36 percent reporting some college attendance or completion of a four-year degree, household incomes were predominantly modest. Nearly two-thirds of participants, or 64.15 percent, reported annual household incomes below fifty thousand dollars, including 13.20 percent earning under ten thousand dollars annually. Coverage profiles were similarly varied, with 35.84 percent enrolled in employer-sponsored health plans, 33.96 percent utilizing Medicaid or Medicare, 15.09 percent relying on other public insurance, and 1.88 percent lacking healthcare coverage entirely.
The primary qualitative findings revealed that rigid refill timing restrictions represent one of the most immediate and intractable obstacles confronting individuals prescribed controlled anti-seizure medications. This structural barrier produced immediate crises when patients planned travel, as demonstrated by one participant who was forced to cancel a planned two-week out-of-state trip because the pharmacy could not release medication until two days prior to total depletion. Furthermore, when narrow refill windows finally opened, local pharmacies often did not maintain less common scheduled anti-seizure medications in stock. One participant described submitting a refill request two weeks early following clinical self-management guidance, encountering an immediate regulatory block, and subsequently facing an out-of-stock delay that caused complete medication exhaustion and multiple breakthrough seizures.
Compounding these administrative hurdles, geographic isolation and severe transportation barriers amplified the burden of obtaining scheduled pharmaceuticals, particularly because uncontrolled seizures legally prevent many individuals with epilepsy from operating motor vehicles. In rural and underserved environments, visiting a licensed dispensing pharmacy requires coordinated transit planning, commercial transport expenses, or substantial reliance on family members and informal care networks. One rural participant recounted traveling more than an hour into town after being informed a prescription was ready, only to be turned away because regulatory restrictions prohibited release five days early. Because the participant could not drive due to epilepsy, securing another ride three days later created immense logistical disruption and delay. Inflexible hourly employment schedules and childcare responsibilities further exacerbated these challenges, especially when pharmacies dispensed only partial fills due to inventory constraints. As another participant noted, receiving an emergency partial supply required navigating identical travel hurdles and work disruptions several days later to secure the remainder of the prescription.
Over extended time horizons, navigating this persistent administrative friction exacts a profound psychological and emotional toll, actively undermining the very self-management behaviors clinicians encourage patients to adopt. Interview narratives detailed how repeated encounters with conflicting bureaucratic rules generated chronic anticipatory anxiety, helplessness, and demoralizing frustration. One participant described fighting with pharmacies for six consecutive months over regulatory delays, enduring relentless stress every refill cycle, and ultimately contemplating stopping anti-seizure therapy altogether under the fatalistic conviction that whatever happens, happens. The clinical danger of such treatment fatigue cannot be overstated, as prior epidemiological research demonstrates that medication nonadherence carries catastrophic medical risks.
The patient-reported experiences documented in the MINDSET 2.0 qualitative cohort demonstrated striking convergence with recent national clinician data, highlighting a systemic rather than localized failure of calibration. In a landmark 2026 nationwide survey conducted by de Leon Ernst and colleagues encompassing 236 neurology physicians and advanced practice providers, 99 percent reported encountering patients who faced severe refill difficulties or missed medication days directly attributable to controlled-substance restrictions. Furthermore, 73 percent of clinicians acknowledged that controlled-substance scheduling actively influenced their choice of anti-seizure therapy. This widespread clinical friction stands in sharp contrast to measured diversion risks, as clinicians reported perceived misuse rates of merely 1 percent for brivaracetam and lacosamide, and zero percent for perampanel and cenobamate, challenging the clinical proportionality of current statutory classifications.
To evaluate whether these regulatory distortions represent an isolated specialty dilemma or a universal structural vulnerability, the investigators conducted a targeted narrative review examining controlled-substance policies across chronic pain and attention-deficit/hyperactivity disorder. In chronic noncancer pain management, aggressive prescribing caps, legal liabilities, and heightened regulatory scrutiny induced severe treatment disruptions, with one simulated-patient study showing that 40.7 percent of primary care clinics outright refused to accept new patients receiving prescribed opioids. Across all disease contexts, wealthier families with private transportation, financial reserves, and flexible schedules navigated supply disruptions far more effectively, confirming that rigid diversion safeguards consistently exacerbate underlying socioeconomic and health inequities.
In response to these pervasive clinical disruptions, the study authors argue that future controlled-substance governance must be evaluated using a balanced, dual public health standard that weighs diversion prevention equally alongside the preservation of continuous medical access. Achieving this balance requires transitioning away from static statutory designations toward dynamic, evidence-based regulatory proportionality, wherein federal authorities systematically reassess scheduling parameters using real-world postmarketing safety data, actual misuse prevalence, and documented access-related harms. At the health-system and state levels, the investigators recommend developing standardized communication protocols between prescribers, pharmacies, and commercial payers, including dedicated medication-access navigators who resolve inventory bottlenecks and prior authorizations before patient supplies expire.
Subject of Research: Qualitative evaluation of controlled-substance regulatory barriers affecting medication continuity and health equity in epilepsy care
Article Title: When regulation disrupts treatment: controlled-substance policies, continuity of chronic disease care, and health equity
Article References: Sepulveda, R., Shegog, R., Saljuqi, A. T., Czerniak, K., Addy, R., Erdelyi, C. L., Soto, S., Hernández Zetina, M., Martin, K., & Labiner, D. (2026). When regulation disrupts treatment: controlled-substance policies, continuity of chronic disease care, and health equity. Frontiers in Public Health, 14, Article 2006216. https://doi.org/10.3389/fpubh.2026.2006216
Image Credits: AI Generated
DOI: 10.3389/fpubh.2026.2006216
Keywords: epilepsy, anti-seizure medications, controlled substances, Controlled Substances Act, treatment continuity, breakthrough seizures, MINDSET 2.0, health equity, refill restrictions, pharmacy stock delays, public health policy, medication access, neurology, chronic disease care, diversion control, administrative burden, prescription drug monitoring
News Source: Kendall Mcintyre. (November 17, 2026). Controlled Substance Rules Disrupt Epilepsy Care and Trigger Breakthrough Seizures. Scienmag.



